Glucose Lavoisier

Glucose Lavoisier is an intravenous solution containing glucose as the active ingredient. It is supplied as a sterile solution for injection, marketed in the European Union. The product provides a readily available source of carbohydrate energy and is used in clinical settings for parenteral nutrition, treatment of hypoglycemia, and fluid and electrolyte replacement. Formulation strength is not specified in the available data, currently publicly disclosed by the manufacturer.

Glucose Lavoisier is indicated for clinical situations where rapid carbohydrate supplementation or fluid replacement is required, particularly in hospital or intensive‑care environments. It may be administered intravenously as part of a broader therapeutic regimen.

- Management of acute hypoglycemia when oral glucose is not feasible. - Component of parenteral nutrition formulas for patients unable to eat orally. - Support of fluid and electrolyte balance during peri‑operative care. - Treatment of dehydration combined with carbohydrate loss in critical illness. - Adjunct in metabolic testing or glucose tolerance assessments under medical supervision.

Intravenous administration of Glucose Lavoisier can produce a spectrum of physiological responses, most of which are directly related to the rapid increase in plasma glucose and the osmotic load of the solution, and are generally predictable in clinical practice.

Common: - Transient elevation of blood glucose levels, typically observed within minutes of infusion and returning to baseline after cessation. - Mild gastrointestinal discomfort such as nausea or occasional vomiting, especially with rapid infusion rates. - Local irritation or erythema at the catheter insertion site, which usually resolves without intervention.

Serious: - Significant hyperglycemia that may require insulin therapy or adjustment of the glucose infusion rate. - Fluid overload leading to pulmonary edema, particularly in patients with compromised cardiac or renal function. - Electrolyte disturbances, including hyponatremia or hypokalemia, resulting from shifts associated with glucose metabolism.

Prior to using Glucose Lavoisier, clinicians should evaluate patient-specific factors and monitor relevant parameters to minimize risks associated with intravenous carbohydrate administration.

- Assess baseline blood glucose and adjust infusion rate in diabetic patients. - Monitor fluid balance to avoid overload, especially in patients with cardiac or renal impairment. - Check serum electrolytes before and during therapy to detect shifts. - Use aseptic technique to prevent catheter‑related infections. - Avoid rapid infusion in neonates or patients with compromised vascular integrity. - Review compatibility with other intravenous solutions to prevent precipitation.

Glucose Lavoisier may interact with other medications or solutions administered intravenously, influencing glucose metabolism or solution stability.

Avoid: - Co‑administration with insulin infusions without appropriate dose adjustment. - Mixing with calcium‑containing solutions that can cause precipitation.

Use with caution: - Concurrent use of glucocorticoids, which may exacerbate hyperglycemia. - Administration alongside diuretics that affect fluid balance. - Use with beta‑adrenergic agonists that can increase glucose production.